ArticleNeuro-oncology practice2016
Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis.
Article in Neuro-oncology practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06271421 (Application of Nanoparticles for Cyclic Hyperthermia In Adjuvant Therapy of gLioblastoma Multiforme), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Application of Nanoparticles for Cyclic Hyperthermia In Adjuvant Therapy of gLioblastoma Multiforme (ANCHIALE)
Who cites it
34 citing papers in PubMed, 59 citations in OpenAlex.
- Study of Adaptive Radiotherapy for High-Grade Glioma Based on Interfraction MRI.Cancer medicine · 2026Trial
- Advancing Precision in Neuro-Oncology with Intraoperative Imaging and Fluorescence Guidance: A Narrative Review.Biomedicines · 2025Review
- Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection.Bioengineering (Basel, Switzerland) · 2025Article
- Comparison of Quality of Life in Postoperative High-Grade Glioma Patients Treated Using EORTC and RTOG Target Delineation Techniques for Postoperative Radiotherapy.Asian journal of neurosurgery · 2025Article
- Comparable long term psychosocial burden in patients with lower grade versus higher grade brain tumors.Scientific reports · 2025Article
- Toxicological insights and safety considerations of vorasidenib in grade 2 astrocytoma and oligodendroglioma.International journal of surgery (London, England) · 2025Article
- Relative, Conditional, and Overall Survival and Causes of Death in Patients With Glioblastoma: A Retrospective Longitudinal Cohort Study.Journal of clinical medicine research · 2025Article
- Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumors.Neuro-oncology · 2025Article
- miR-200 family as new potential prognostic factor of overall survival of patients with WHO G2 and WHO G3 brain gliomas.Scientific reports · 2024Article
- Prognostic Role of Invasion-Related Extracellular Matrix Molecules in Diffusely Infiltrating Grade 2 and 3 Astrocytomas.Brain sciences · 2024Article
- Carbon-ion radiotherapy alone vs. standard dose photon radiation with carbon-ion radiotherapy boost for high-grade gliomas: a retrospective study.BMC cancer · 2024Article
- Identification and Validation of a PEX5-Dependent Signature for Prognostic Prediction in Glioma.Biomolecules · 2024Article
- Article
- Long-Term Tumor Control Following Targeted Alpha Therapy (TAT) of Low-Grade Gliomas (LGGs): A New Treatment Paradigm?International journal of molecular sciences · 2023Article
- Carbon-ion radiotherapy boost with standard dose proton radiation for incomplete-resected high-grade glioma: a phase 1 study.Annals of translational medicine · 2022Article
- A Systematic Review and Meta-analysis of the Impact of Radiation-Related Lymphopenia on Outcomes in High-Grade Gliomas.South Asian journal of cancer · 2022Article
- Ketogenic Metabolic Therapy for Glioma.Cureus · 2022Article
- Patients' Survival with Astrocytoma After Treatment: a Systematic Review and Meta-analysis of Clinical Trial Studies.Indian journal of surgical oncology · 2022Review
- Risk Factors Associated with Malignant Transformation of Astrocytoma: Competing Risk Regression Analysis.Asian journal of neurosurgery · 2022Article
- A Population-Based Study of Treatment and Survival in Older Glioma Patients.JNCI cancer spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe survival trends and the patterns of clinical practice pertaining to radiation therapy and surgical resection for WHO grade I, II, and III astrocytoma patients remain poorly characterized.
methodsUsing the Surveillance, Epidemiology and End Results (SEER) database, we identified 2497 grade I, 4113 grade II, and 2755 grade III astrocytomas during the period of 1999-2010. Time-trend analyses were performed for overall survival, radiation treatment (RT), and the extent of surgical resection (EOR).
resultsWhile overall survival of grade I astrocytoma patients remained unchanged during the study period, we observed improved overall survival for grade II and III astrocytoma patients (Tarone-Ware
conclusionResults from the SEER database indicate that there were improvements in the overall survival of grade II and III astrocytoma patients over the past decade. Analysis of the clinical practice patterns identified potential opportunities for impacting the clinical course of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.